SCHEMBL7564804

SCHEMBL7564804

Oc1cccc2c1CCCC(NCc1ccccc1)C2

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 8/20 0.61
DRD3 P35462 4/20 0.61
GRIN2B Q13224 3/20 0.59
FYN P06241 1/20 0.56
DRD4 P21917 2/20 0.55
SIGMAR1 Q99720 1/20 0.49
CA1 P00915 2/20 0.45
CA2 P00918 2/20 0.45
ACHE P22303 2/20 0.45
DRD1 P21728 3/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
TSHR P16473 1/20 0.45
NFKB1 P19838 1/20 0.45
THPO P40225 1/20 0.45
BCL2L1 Q07817 1/20 0.44
BAD Q92934 1/20 0.44
LMNA P02545 1/20 0.44
PMP22 Q01453 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10043007 0.92 DRD2 (0.71) DRD2DRD3GRIN2BFYNDRD4
SCHEMBL11960199 0.92 DRD2 (0.71) DRD2DRD3GRIN2BFYNDRD4
SCHEMBL10043005 0.92 DRD2 (0.71) DRD2DRD3GRIN2BFYNDRD4
SCHEMBL5142084 0.82 GRIN2B (0.82) DRD2DRD3GRIN2BFYNSIGMAR1
SCHEMBL5143976 0.81 DRD2 (0.86) DRD2DRD3GRIN2BDRD4SIGMAR1
SCHEMBL11075369 0.79 DRD2 (0.70) DRD2DRD3GRIN2BDRD4SIGMAR1
SCHEMBL10043003 0.78 DRD2 (0.71) DRD2DRD3GRIN2BFYNDRD4
SCHEMBL10043001 0.78 DRD2 (0.71) DRD2DRD3GRIN2BFYNDRD4
SCHEMBL11960195 0.78 DRD2 (0.71) DRD2DRD3GRIN2BFYNDRD4
Hydrochloric Acid SCHEMBL5144066 0.77 KMT2A (0.56) DRD2DRD3DRD4CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6391915-B2 ANTIULCER AGENTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-05-21 US disclosed
US-20020006956-A1 Propanolamine derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-01-17 US disclosed
EP-0976720-A1 PROPANOLAMINE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-02-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020006956-A1 Propanolamine derivatives PNLIP, ADRB1, FABP2 DRD2 115/4885DRD3 103/4885GRIN2B 3560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.